Thomas Shrader
Stock Analyst at BTIG
(3.35)
# 1,008
Out of 5,014 analysts
53
Total ratings
48%
Success rate
5.52%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COYA Coya Therapeutics | Reiterates: Buy | $15 | $6.27 | +139.23% | 2 | Sep 30, 2025 | |
| HROW Harrow | Reiterates: Buy | $63 | $40.57 | +55.29% | 3 | Sep 29, 2025 | |
| ALEC Alector | Reiterates: Buy | $5 | $3.14 | +59.24% | 3 | Sep 25, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | $72 | $61.41 | +17.24% | 1 | Sep 8, 2025 | |
| GANX Gain Therapeutics | Reiterates: Buy | $9 | $2.08 | +332.69% | 3 | Sep 8, 2025 | |
| ACIU AC Immune | Reiterates: Buy | $8 | $3.48 | +129.89% | 2 | Sep 8, 2025 | |
| BHVN Biohaven | Maintains: Buy | $59 → $60 | $17.23 | +248.23% | 3 | Aug 19, 2025 | |
| INMB INmune Bio | Downgrades: Neutral | n/a | $1.98 | - | 3 | Jul 1, 2025 | |
| ALDX Aldeyra Therapeutics | Maintains: Buy | $11 → $9 | $5.67 | +58.73% | 1 | Apr 7, 2025 | |
| OVID Ovid Therapeutics | Maintains: Buy | $5 → $4 | $1.74 | +129.89% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $41.99 | +281.04% | 4 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $19.68 | +108.33% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.92 | - | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.51 | +1,468.63% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $5.88 | +920.41% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $3.26 | +114.72% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $1.02 | +1,174.51% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $2.25 | +877.78% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.54 | +3,211.69% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.75 | +326.67% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.15 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.17 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $58 | $14.87 | +290.05% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.39 | +115.83% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $149.61 | +131.27% | 3 | Feb 21, 2019 |
Coya Therapeutics
Sep 30, 2025
Reiterates: Buy
Price Target: $15
Current: $6.27
Upside: +139.23%
Harrow
Sep 29, 2025
Reiterates: Buy
Price Target: $63
Current: $40.57
Upside: +55.29%
Alector
Sep 25, 2025
Reiterates: Buy
Price Target: $5
Current: $3.14
Upside: +59.24%
Bright Minds Biosciences
Sep 8, 2025
Initiates: Buy
Price Target: $72
Current: $61.41
Upside: +17.24%
Gain Therapeutics
Sep 8, 2025
Reiterates: Buy
Price Target: $9
Current: $2.08
Upside: +332.69%
AC Immune
Sep 8, 2025
Reiterates: Buy
Price Target: $8
Current: $3.48
Upside: +129.89%
Biohaven
Aug 19, 2025
Maintains: Buy
Price Target: $59 → $60
Current: $17.23
Upside: +248.23%
INmune Bio
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.98
Upside: -
Aldeyra Therapeutics
Apr 7, 2025
Maintains: Buy
Price Target: $11 → $9
Current: $5.67
Upside: +58.73%
Ovid Therapeutics
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.74
Upside: +129.89%
Feb 24, 2025
Reiterates: Buy
Price Target: $160
Current: $41.99
Upside: +281.04%
Jan 28, 2025
Initiates: Buy
Price Target: $41
Current: $19.68
Upside: +108.33%
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.92
Upside: -
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $0.51
Upside: +1,468.63%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $5.88
Upside: +920.41%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $3.26
Upside: +114.72%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $1.02
Upside: +1,174.51%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $2.25
Upside: +877.78%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.54
Upside: +3,211.69%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $3.75
Upside: +326.67%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $5.15
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.17
Upside: -
Sep 15, 2020
Maintains: Buy
Price Target: $51 → $58
Current: $14.87
Upside: +290.05%
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.39
Upside: +115.83%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $149.61
Upside: +131.27%